
LH Stock Forecast & Price Target
LH Analyst Ratings
Bulls say
Labcorp Holdings has demonstrated robust revenue growth, with the Central Lab segment achieving a remarkable $554.7 million in revenue, reflecting a 7.5% increase driven by significant trial wins and the incorporation of digital pathology capabilities. The Diagnostic segment also continues to perform well, reporting $2.75 billion in revenue, which represents an 8.9% year-over-year increase, supported by both organic growth and acquisitions. Additionally, the company exhibits a strong order backlog of $8.71 billion, which is up approximately 10% year-over-year, coupled with a trailing twelve-month net book-to-bill ratio of 1.11x, indicating continued positive momentum in demand for its services.
Bears say
The analysis highlights several fundamental risks contributing to a negative outlook on Labcorp Holdings' stock. Key concerns include potential adverse shifts in reimbursement policies, challenges related to the integration of acquisitions, and escalating competition within the clinical laboratory market. Additionally, ongoing economic uncertainty coupled with potential regulatory challenges further threatens the company's financial stability and future performance.
This aggregate rating is based on analysts' research of Labcorp Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
LH Analyst Forecast & Price Prediction
Start investing in LH
Order type
Buy in
Order amount
Est. shares
0 shares